These authors contributed equally to this work.
Swietenia mahagony extract shows agonistic activity to PPAR γ and gives ameliorative effects on diabetic db/db mice
Article first published online: 27 JAN 2005
Acta Pharmacologica Sinica
Volume 26, Issue 2, pages 220–222, February 2005
How to Cite
LI, D.-d., CHEN, J.-h., CHEN, Q., LI, G.-w., CHEN, J., YUE, J.-m., CHEN, M.-l., WANG, X.-p., SHEN, J.-h., SHEN, X. and JIANG, H.-l. (2005), Swietenia mahagony extract shows agonistic activity to PPAR γ and gives ameliorative effects on diabetic db/db mice. Acta Pharmacologica Sinica, 26: 220–222. doi: 10.1111/j.1745-7254.2005.00527.x
- Issue published online: 27 JAN 2005
- Article first published online: 27 JAN 2005
- Received 2004-09-24; Accepted 2004-11-09
- Swietenia mahagony;
- diabetes mellitus;
- peroxisome proliferator-activated receptor γ;
- yeast-two hybrid
Aim: To search the peroxisome proliferator-activated receptor γ (PPARγ) agonists from Swietenia mahagony extract (SmE) and observe the possible ameliorative effects of SmE on diabetic db/db mice.
Methods: The PPARγ agonistic activity of SmE was screened by yeast-two hybrid system. The blood glucose levels of diabetic db/db mice were measured using a blood glucose level monitor and the data were statistically analyzed by NDST8.8W software.
Results: By using the clinical drug rosiglitazone as a positive control, it was found that the PPARγ agonistic activity of SmE at a concentration of 50 μg/L was approximately half that of 35.7 μg/L (0.1 μmol/L) of rosiglitazone. At the dose of 1000 mg/kg, SmE remarkably decreased the blood glucose concentration of db/db mice from (15.26±2.98) to (7.58±2.20) mmol/L, and reduced the blood glucose levels by 55.49% compared with the control group (P<0.01).
Conclusion: SmE shows agonistic activity to PPARγ and can ameliorate the blood glucose levels of diabetic db/db mice. SmE may be thus used as a potential agent for diabetes therapy.